Pharmaceutical Deviation and OOS Investigation Workflow

By Jackson T on October 23, 2026

pharmaceutical-deviation-oos-investigation-workflow

An out-of-specification result is a question the lab has to answer, not just a number to retest. Answer it badly and auditors will find the gaps: a result invalidated without proof, a retest count set after the fact, or other batches that were never checked. A clear OOS investigation workflow gives every case the same phases, the same evidence and the same closure. See how the phased workflow runs in a short OOS workflow demo.

OOS WORKFLOW · PHARMA QUALITY

Run Every OOS Result Through the Same Phased Investigation

iFactory OOS Workflow opens a phased investigation template the moment a result fails, attaches the lab data, and assesses batch impact through genealogy. When the case closes, the CAPAs it raised stay linked to it.

OOS-118 · Assay, Lot 4471Phase I open
Opened 09:42 · Analyst and supervisor notified
Reportable result93.1%
Specification95.0 – 105.0%
Test preparationsRetained
Calculations ✓ Instrument ✓ Standards ✓ Raw data review
Genealogy: 3 linked lots flagged for impact review
PHARMA DEVIATION, OOS AND OOT

Three Signals, Three Different Starting Points

Teams often lump these together, but each one opens a different path. A deviation is about how the work was done. An OOS is about a result that fails. An OOT result still passes but breaks the expected pattern. Getting the label right on day one decides who investigates and what evidence is needed. Talk through your own triage rules with our quality team.

Deviation
An unplanned event or a difference from procedures or standardsExample: a mixing step ran 10 minutes longer than the batch record allows. Investigated as a deviation, with impact on quality assessed.
OOS
Any test result outside the specification or acceptance criteriaCovers release, stability and in-process lab tests. FDA expects an investigation every time, under 21 CFR 211.192.
OOT
A result within limits that falls outside the expected trendOften defined as a time-based result outside a prediction interval or failing a statistical control rule, such as a stability point.
FDA OOS GUIDANCE

What the 2006 Guidance and Its 2022 Revision Set Out

FDA first issued "Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production" in October 2006 and published Revision 1 in May 2022. The definition of OOS did not change. The guidance covers traditional lab testing and release, not process analytical technology (PAT) approaches. It sets out a phased path from the first failing number to a final batch decision. Map your current SOP against it in a guided workflow review.

1ReportAnalyst informs the supervisor and keeps the test preparations
2Phase ILab investigation looks for a clear, documented lab error
3DecideError proven: invalidate. Not proven: escalate
4Phase IIFull-scale review of production plus extra lab testing
5ConcludeQuality unit interprets results and decides the batch
What Revision 1 changed

Minor wording edits, the term quality control unit (QCU) replaced by quality unit (QU), outlier tests limited to an informational role, and a new subsection on averaging replicate results from the same final sample preparation.

PHASE I INVESTIGATION

Analyst and Supervisor: Who Checks What

Phase I is a lab investigation, done quickly and without assumptions. The guidance is clear that a result can be invalidated only when a test event is observed and documented. It also says laboratory error should be relatively rare, and frequent errors point to problems such as analyst training or equipment upkeep. Get a sample Phase I checklist from our support team.

ANALYST RESPONSIBILITIES
  • Use only calibrated instruments that meet performance specifications
  • Check data against the specification before throwing away test preparations
  • Keep the preparations, if stable, and tell the supervisor at once
  • Never knowingly continue an analysis expected to be invalidated later
SUPERVISOR RESPONSIBILITIES
  • Confirm the correct method and procedure were followed
  • Examine raw data, such as chromatograms and spectra
  • Verify all calculations and instrument performance
  • Confirm standards, reagents and method performance against validation data
  • Document and preserve every record of the assessment
Assignable cause

Only clear, documented evidence of a lab error, such as a wrong dilution or an instrument fault, supports invalidating the original result. If no error is found, the case moves to Phase II.

PHASE II INVESTIGATION

No Lab Error Found? The Production Floor Gets Reviewed

A full-scale investigation is led by the quality unit, with production, engineering and the lab contributing. It reviews how the batch was made and sampled, and the written record should state the reason for the investigation, the likely causes, whether the problem has happened before and the actions taken. The MHRA's OOS guidance, first published in August 2013, describes the same step as a manufacturing investigation. Plan the hand-off between lab and production in a Phase II design session.

01
Batch recordSteps, times, yields and any recorded deviations during the run
02
EquipmentMaintenance, cleaning and calibration status of the line used
03
MaterialsAPI and excipient lots, supplier results and storage conditions
04
SamplingHow, where and by whom the sample was taken and handled
05
HistorySimilar failures on this product, line, method or material
06
Extra testingRetests or resamples run to a written, pre-approved plan

One Case File From First Result to Closure

iFactory keeps the failing result, raw data, Phase I checks, production review and batch decision in one investigation. Linked lots surface through genealogy, and CAPAs stay attached when the case closes.

QC lab · QA lead and iFactory
QA leadPhase I on OOS-118 found no lab error. What else used API lot A-209?
iFactoryTwo other batches, 4468 and 4473. Batch 4468 is released, 4473 is in quarantine.
QA leadOpen Phase II and add both to the impact review.
iFactoryDone. Phase II template opened with both batches listed for QA review.
OOS INVESTIGATION WORKFLOW BEST PRACTICES

The Rules for Retesting, Resampling, Averaging and Outliers

Extra testing is where most OOS findings start. The guidance calls "testing into compliance" unscientific and objectionable, and says all results, passing and suspect, should be reported and considered in the batch decision. The matrix shows what each rule allows and how a workflow can hold the line. Check your own retest SOP with our QA specialists.

Practice
What the FDA guidance says
What it rules out
How the workflow enforces it
Retesting
Retest the same homogeneous material, ideally by a second analyst at least as qualified
Changing the number of retests based on the results
Retest count fixed in the SOP
Resampling
Test extra units or a new sample when the original sample was not representative or badly prepared
Using an unvalidated sampling method
QU approval before new sampling
Averaging
Valid when the method itself specifies it, such as replicate injections
Averaging the original result with retests to hide variability
Every result shown separately
Mixed results
If some individual results fail and others pass, treat the average as OOS
Reporting a passing average over failing values
Flag any failing individual
Outlier tests
Informational only. May suit biological assays with high variability
Invalidating a validated chemical test result as an outlier
Outlier output cannot invalidate
Product variability tests
Content uniformity and dissolution measure real unit-to-unit spread
Outlier tests on these results
Outlier option switched off
CONCLUDING THE INVESTIGATION

Four Ways an OOS Case Can End

The quality unit interprets the findings and makes the batch decision. A confirmed OOS means the batch does not meet its specification and should be rejected. When the outcome is inconclusive, the guidance says the QU should always err on the side of caution. Rehearse your closure criteria in an investigation closure demo.

Invalidated
Documented lab error found in Phase I. The valid retest result is reported.
Confirmed OOS
Batch fails its specification and is rejected. Other batches are assessed.
Inconclusive
The OOS result gets full weight in the disposition decision.
Field alert
For NDA and ANDA products, a distributed batch failure is reported to FDA within 3 working days.
IMPACT ASSESSMENT

Batch Impact Through Genealogy

21 CFR 211.192 requires a thorough investigation of any batch failure, whether or not the batch has been distributed, and says it must extend to other batches of the same product and other products that may be associated with the failure. Genealogy turns that from a search through paper into a query. Ask our support team how lot links are built from your ERP and batch records.

LOOK UPSTREAM
Where did the inputs come from?API, excipient and packaging lots used in the failing batch, plus supplier results and receiving checks.
LOOK SIDEWAYS
What else shared the cause?Batches made with the same material lot, equipment train, campaign, method or analyst.
LOOK DOWNSTREAM
Where did the product go?Finished lots, released and distributed stock, and stability samples on study.
CAPA LINKAGE · ICH Q10

Close the Loop With Corrective and Preventive Action

ICH Q10 expects a CAPA system that takes in deviations, non-conformances, product rejections and trends, uses a structured approach to find the root cause and scales the effort to the level of risk. An OOS that closes without a linked action, or with a CAPA that is never checked, is a gap. Plan your CAPA links in a CAPA linkage session.

Root cause statedLab, manufacturing, material or not found, with the evidence for it
CAPA raised and linkedEach action points back to the case and the case to each action
Effectiveness checkA dated check that the fix worked, owned by a named person
Repeat failuresSame product, method or line failing again within a set period
Lab error shareInvalidated cases as a share of all OOS, watched for a rising trend
Cycle timeDays from first result to QU decision, by phase
OOS INVESTIGATION WORKFLOW SOFTWARE

The Fields Every Investigation Record Should Hold

Whatever system you use, the record should let a reviewer follow the case without asking anyone. These are the fields iFactory's template carries by default, and your SOP can add more. Ask our QA specialists for a blank version.

Result and limitValue, specification, method, instrument
Phase I checksAnalyst and supervisor items, signed
HypothesisSuspected cause and the test plan
Extra testingRetest or resample plan, approved first
Production reviewBatch record, equipment, materials
Impact listLinked lots from genealogy
ConclusionInvalidated, confirmed or inconclusive
ClosureQU decision, CAPA links, signatures
OOS INVESTIGATION WORKFLOW COST AND ROI

Size the Hours Spent Assembling Each Case

The biggest risk of a weak OOS process is a regulatory finding, which is hard to price and should not be guessed. What you can size is the time spent pulling raw data, batch records and lot histories together by hand. The figures below are assumed inputs to show the arithmetic only. Build the case with your own numbers in a sizing call.

OOS investigations per year40, assumed
Hours per case gathering records by hand6, assumed
Hours per year spent gathering40 × 6 = 240 hours
Hours per case with records attached automatically2, assumed
Hours per year returned to the lab and QA40 × (6 − 2) = 160 hours

Add the value of fewer late cases, faster batch decisions and cleaner inspection records, but only where your own data supports a figure.

TURNKEY AI DEPLOYMENT

Implementation Guide: OOS Workflow and AI Server in One Package

iFactory delivers OOS Workflow as a turnkey package. A pre-configured NVIDIA AI server ships racked and ready, so investigation records, lab data and genealogy stay on your site and the AI can flag linked lots and repeat failures locally. You rack it, plug in power and Ethernet, and the AI is live. Scope the rollout with our implementation team.

What's Included
  • Pre-configured NVIDIA AI server, racked and ready
  • Phase I and Phase II investigation templates
  • LIMS and instrument data links for raw results
  • Batch genealogy from ERP and batch records
  • CAPA module linked to each investigation
  • Audit trails and e-signatures on every decision
  • 24×7 remote monitoring of platform and hardware
Live in 6–12 weeks
Wk 1–4
Map and Connect

OOS SOP mapped to templates, server installed, LIMS and ERP links set up.

Wk 5–8
Validate and Pilot

Workflow validated and piloted on one lab and product family.

Wk 9–12
Go Live and Train

All labs live, analysts and QA trained, trend reviews started.

HOW iFACTORY FITS

An OOS Workflow That Follows the Guidance

iFactory is built so the phased approach is the easy path, not an extra burden on the lab. See it on your own SOP in a workflow demo.

1
Phased templates. Phase I and Phase II open in order, with checks set by your SOP.
2
Lab data attached. Raw results, chromatograms and instrument records sit in the case.
3
Impact through genealogy. Linked lots upstream, sideways and downstream are listed for review.
4
CAPAs linked on closure. Actions and effectiveness checks stay tied to the case.
1000+
Industrial clients running iFactory
99.9%
Platform uptime for regulated sites
6-12 wks
From racked server to live investigations
FREQUENTLY ASKED QUESTIONS

OOS Investigation Workflow for Plant Managers and QA

What is the difference between a Phase I and a Phase II investigation?
Phase I is a lab investigation by the analyst and supervisor, looking for a clear, documented laboratory error. Phase II is a full-scale investigation led by the quality unit when no lab error is found. It reviews production and sampling, and may include retesting or resampling to a pre-approved plan.
When can an OOS result be invalidated?
Only when a test event that caused the error is observed and documented. The FDA guidance says laboratory error should be relatively rare. A passing retest on its own is not proof that the first result was wrong.
How many retests are allowed?
The guidance does not set a number. It says the maximum number of retests should be specified in advance in a written SOP and not adjusted based on the results. All results, passing and failing, are reported and considered.
Can an outlier test remove a failing chemical assay result?
No. For validated chemical tests with small variance, an outlier test cannot invalidate a result, and Revision 1 limits outlier tests to an informational role. They may suit biological assays with high variability, and they are not used where real product spread is measured, such as content uniformity or dissolution.
Does an OOS investigation have to cover other batches?
Yes. 21 CFR 211.192 requires the investigation to extend to other batches of the same product and other products that may be associated with the failure. Batch genealogy is the fastest way to find them.
How do we start without disrupting the lab?
Start with one lab and one product family. Map your OOS SOP into the Phase I and Phase II templates, connect lab data and batch records, and run new cases in the workflow while closing older ones as before. Our support team can plan that pilot with you.

Make Every OOS Case Defensible

Phased templates, attached lab data, genealogy-based impact review and linked CAPAs, delivered turnkey and live in 6 to 12 weeks.

Example case summary · OOS-118
Phase INo lab error found
Phase IIProduction and material review
Linked lots3 reviewed through genealogy
ClosureQU decision with 2 CAPAs linked
Every step signed and traceable

Share This Story, Choose Your Platform!